- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2018. Label expansion decision pending FDA review (sNDA submitted July 2026, no specific PDUFA date available).
- Why 4/10
- The only near-term binary catalyst for ARIKAYCE is the FDA decision on its sNDA for label expansion to newly diagnosed MAC patients (submitted July 2026, no PDUFA date assigned in available data). Even if approved, ARIKAYCE is now a secondary commercial asset, BRINSUPRI drove $309M in a single quarter vs ARIKAYCE's ~$115M quarterly run rate, so the stock impact is moderate at best.
ARIKAYCE is a mature commercial asset for Insmed; the stock's primary driver is now BRINSUPRI's launch trajectory. Investors should watch for the FDA decision on ARIKAYCE's sNDA for label expansion to newly diagnosed MAC patients (timing unconfirmed), but the bigger stock-moving events will likely be BRINSUPRI sales updates and the Japan approval ramp.
Price Chart
Executive Summary
ARIKAYCE (amikacin liposome inhalation suspension) is an approved, marketed inhaled antibiotic from Insmed Incorporated (Nasdaq: INSM) for refractory MAC lung disease, a rare, serious infection. Approved in 2018, it holds a niche but protected position. However, ARIKAYCE is no longer Insmed's flagship product: that title now belongs to BRINSUPRI (brensocatib), which generated $309M in Q2 2026 alone versus ARIKAYCE's guidance of $450-470M for the full year. The key near-term catalyst is an sNDA filed in July 2026 seeking label expansion to newly diagnosed MAC patients, but no PDUFA date has been assigned yet. With strong analyst support (mean PT ~$200) but limited binary catalysts ahead for this specific drug, the investor read is neutral, the stock thesis increasingly depends on BRINSUPRI's blockbuster trajectory, not ARIKAYCE.
How It Works
ARIKAYCE is an inhaled antibiotic (amikacin) packaged inside tiny fat bubbles called liposomes. When the patient breathes it in through a nebulizer, the liposomes deliver a concentrated dose of antibiotic directly to the lungs where the Mycobacterium avium complex (MAC) bacteria live. This targeted delivery allows higher concentrations at the infection site while limiting systemic side effects.
Trial Status
ARIKAYCE was FDA-approved on September 28, 2018 for the treatment of refractory MAC lung disease in adults with limited or no alternative treatment options. It is commercially marketed. An sNDA (supplemental New Drug Application) was submitted to the FDA in July 2026 seeking label expansion to include newly diagnosed MAC lung disease patients. The sNDA is under FDA review (no publicly disclosed PDUFA date in available data). A boxed warning for risk of increased respiratory adverse reactions was added to the label in June 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA decision on sNDA for label expansion to newly diagnosed MAC lung disease patients (submitted July 2026, PDUFA date not yet publicly assigned)
- Quarterly revenue reports showing ARIKAYCE commercial sales trajectory (guidance $450-470M for 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INSMED Inc 8-K INSM ·Originating report